RT Journal Article
T1 Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.
A1 Casanova, María José
A1 Chaparro, María
A1 Mínguez, Miguel
A1 Ricart, Elena
A1 Taxonera, Carlos
A1 García-López, Santiago
A1 Guardiola, Jordi
A1 López-San Román, Antonio
A1 Iglesias, Eva
A1 Beltrán, Belén
A1 Sicilia, Beatriz
A1 Vera, María Isabel
A1 Hinojosa, Joaquín
A1 Riestra, Sabino
A1 Domènech, Eugeni
A1 Calvet, Xavier
A1 Pérez-Calle, José Lázaro
A1 Martín-Arranz, María Dolores
A1 Aldeguer, Xavier
A1 Rivero, Montserrat
A1 Monfort, David
A1 Barrio, Jesús
A1 Esteve, María
A1 Márquez, Lucía
A1 Lorente, Rufo
A1 García-Planella, Esther
A1 de Castro, Luisa
A1 Bermejo, Fernando
A1 Merino, Olga
A1 Rodríguez-Pérez, Antonio
A1 Martínez-Montiel, Pilar
A1 Van Domselaar, Manuel
A1 Alcaín, Guillermo
A1 Domínguez-Cajal, Manuel
A1 Muñoz, Carmen
A1 Gomollón, Fernando
A1 Fernández-Salazar, Luis
A1 García-Sepulcre, Mariana Fe
A1 Rodríguez-Lago, Iago
A1 Gutiérrez, Ana
A1 Argüelles-Arias, Federico
A1 Rodriguez, Cristina
A1 Rodríguez, Gloria Esther
A1 Bujanda, Luis
A1 Llaó, Jordina
A1 Varela, Pilar
A1 Ramos, Laura
A1 Huguet, José María
A1 Almela, Pedro
A1 Romero, Patricia
A1 Navarro-Llavat, Mercè
A1 Abad, Águeda
A1 Ramírez-de la Piscina, Patricia
A1 Lucendo, Alfredo J
A1 Sesé, Eva
A1 Madrigal, Rosa Eva
A1 Charro, Mara
A1 García-Herola, Antonio
A1 Pajares, Ramón
A1 Khorrami, Sam
A1 Gisbert, Javier P
K1 Crohn’s disease
K1 anti-TNF
K1 inflammatory bowel disease
K1 switch
K1 ulcerative colitis
AB The effectiveness of the switch to another anti-tumor necrosis factor (anti-TNF) agent is not known. The aim of this study was to analyze the effectiveness and safety of treatment with a second and third anti-TNF drug after intolerance to or failure of a previous anti-TNF agent in inflammatory bowel disease (IBD) patients. We included patients diagnosed with IBD from the ENEIDA registry who received another anti-TNF after intolerance to or failure of a prior anti-TNF agent. A total of 1122 patients were included. In the short term, remission was achieved in 55% of the patients with the second anti-TNF. The incidence of loss of response was 19% per patient-year with the second anti-TNF. Combination therapy (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.8-3; P  Approximately half of the patients who received a second anti-TNF achieved remission; nevertheless, a significant proportion of them subsequently lost response. Combination therapy and type of IBD were associated with loss of response. Remission was achieved in almost 50% of patients who received a third anti-TNF; nevertheless, a significant proportion of them subsequently lost response.
YR 2020
FD 2020
LK http://hdl.handle.net/10668/14490
UL http://hdl.handle.net/10668/14490
LA en
DS RISalud
RD Apr 11, 2025